Korean Journal of Pediatrics 2005;48(1):55-62.
Published online January 15, 2005.
Comparison of Therapeutic Efficacy between Lamivudine and Alpha-Interferon in Korean Children with Chronic Hepatitis B at Two Years after the Initiation of Treatment
Byung-Ho Choe, You Cheol Jang, Chang Hwan Jang, Ki Won Oh, Jun Hwa Lee, Cheol Woo Ko
Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea
소아 만성 B형 간염 환아에서 라미부딘과 알파 인터페론의 치료효과 비교 : 치료 시작 후 2년 경과 시점 비교
최병호, 장유철, 장창환, 오기원, 이준화, 고철우
경북대학교 의과대학 소아과학교실
Correspondence: 
Byung-Ho Choe, Email: bhchoi@knu.ac.kr
Abstract
Purpose
: We compared the therapeutic efficacy of lamivudine and alpha-interferon in children with chronic hepatitis B two years after the initiation of treatment, so that we could verify the safety and long term efficacy of lamivudine in children.
Methods
: We prospectively studied 44 children(32 male and 12 female; age, 1-18 years, mean, 9 years) treated for chronic hepatitis B from September 1996 to June 2004 in Kyungpook National University Hospital in Korea. Twenty three children were treated with interferon, and 21 with lamivudine. Treatment efficacy was defined as the normalization of ALT and hepatitis B virus(HBV) DNA levels, loss of HBsAg and HBeAg seroconversion at two years after the initiation of treatment.
Results
: Among the 23 children treated with interferon, the ALT level normalized in 10 children(43 %) and HBV DNA was undetectable in 12 children(52%). HBsAg was undetectable in one child (4 %) and HBeAg seroconversion occurred in nine children(39%) two years after the initiation of treatment. In comparison, among the 21 children treated with lamivudine, ALT normalized in 20 children (95%), HBV DNA in 19(90%), HBsAg in 5(24%), and HBeAg seroconversion occurred in 13(62%). Above all, in the lamivudine treated group under the age of seven, HBeAg and HBsAg seroconversion occurred in six(75%) and five(63%) out of the eight children respectively, which showed superior HBsAg seroconversion rate if treated in preschool aged children.
Conclusion
: We believe that the therapeutic efficacy of lamivudine in children with chronic hepatitis B could be better than interferon with fewer side effects, especially in preschool aged children.
Key Words: Chronic hepatitis B, Children, Interferon, Lamivudine, Hepatitis B e antigens, Hepatitis B s antigens, Seroconversion, Treatment


METRICS Graph View
  • 2,176 View
  • 8 Download


Close layer
prev next